SCHEMBL6396182

SCHEMBL6396182

O=C(Cc1ccc(O)cc1)c1c(O)cccc1P(=O)(O)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 1/20 0.46
SGMS1 Q86VZ5 1/20 0.46
SGMS2 Q8NHU3 1/20 0.46
ESR1 P03372 2/20 0.44
SHBG P04278 1/20 0.44
ESR2 Q92731 1/20 0.44
MAPT P10636 4/20 0.42
MEN1 O00255 2/20 0.42
CYP3A4 P08684 2/20 0.42
HPGD P15428 2/20 0.42
MAPK1 P28482 2/20 0.42
KMT2A Q03164 2/20 0.42
PIK3CA P42336 1/20 0.42
FNTA P49354 1/20 0.41
FNTB P49356 1/20 0.41
CA2 P00918 3/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
CAMK2A Q9UQM7 1/20 0.41
LMNA P02545 4/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6397026 0.85 ACHE (0.57) ACHESGMS1SGMS2ESR1MAPT
SCHEMBL6404380 0.85 CTBP2 (0.42) ACHESGMS1SGMS2ESR1SHBG
SCHEMBL6401949 0.83 ACHE (0.66) ACHESGMS1SGMS2ESR1MAPT
SCHEMBL6396380 0.82 MAPT (0.56) ACHESGMS1SGMS2ESR1SHBG
SCHEMBL6398669 0.78 ACHE (0.43) ACHESGMS1SGMS2ESR1SHBG
SCHEMBL6396177 0.78 ACHE (0.43) ACHESGMS1SGMS2ESR1SHBG
SCHEMBL6397760 0.76 ESR1 (0.36) ACHESGMS1SGMS2ESR1ESR2
SCHEMBL6399719 0.74 SLC5A1 (0.48) ACHESGMS1SGMS2ESR1MAPT
SCHEMBL6396398 0.72 LMNA (0.49) ESR1SHBGESR2MAPTMEN1
SCHEMBL6403060 0.72 ACHE (0.50) ACHESGMS1SGMS2MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050187195-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans PEERCE BRIAN E (US) 2005-08-25 US disclosed
US-6787528-B2 THERAPY FOR KIDNEY DISEASES BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2004-09-07 US disclosed
US-20030162753-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2003-08-28 US disclosed
US-20020133036-A1 Inhibitors of intestinal apical membrane Na/phosphate co-transportation PEERCE BRIAN E (US) 2002-09-19 US disclosed
US-6355823-B1 MEMBRANE SUBSTRATE PHOSPHATED FOR DRUGS FOR GASTROINTESTINAL DISORDERS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2002-03-12 US disclosed
EP-1175425-A2 INHIBITORS OF INTESTINAL APICAL MEMBRANE NA/PHOSPHATE CO-TRANSPORTATION THE BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2002-01-30 EP disclosed
WO-2000043402-A2 INHIBITORS OF INTESTINAL APICAL MEMBRANE NA/PHOSPHATE CO-TRANSPORTATION BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2000-07-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050187195-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans SLC34A3, SLC34A1, SLC34A2 ACHE 4868/4885SGMS1 3968/4885SGMS2 4314/4885
US-20020133036-A1 Inhibitors of intestinal apical membrane Na/phosphate co-transportation SLC10A2, SLC34A3, SLC34A1 ACHE 4865/4885SGMS1 4101/4885SGMS2 4281/4885
US-20030162753-A1 Inhibition of intestinal apical membrane Na/phosphate co-transportation in humans SLC34A3, SLC34A1, SLC34A2 ACHE 4868/4885SGMS1 3968/4885SGMS2 4314/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.